zaloglanstat

Zaloglanstat (GRC 27864) is a potent, selective, and orally bioavailable small molecule inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme upregulated under inflammatory conditions and involved in the biosynthesis of prostaglandin E2. By inhibiting mPGES-1, zaloglanstat targets a novel pathway for pain management distinct from traditional NSAIDs that inhibit upstream cyclooxygenase enzymes. The drug has been developed primarily for the treatment of inflammatory pain and osteoarthritis. Clinical studies have included Phase I trials evaluating safety and pharmacokinetics in healthy adults and elderly subjects as well as Phase IIb trials assessing efficacy in patients with moderate osteoarthritis pain[1][2][5][6][7].

Other names

zaloglanstatGRC 27864GRC27864GRC-27864ISC-27864ISC27864ISC 27864